Back to Search
Start Over
Introduction of novel agents in the treatment of primary CNS lymphoma
- Source :
- Neuro-oncology. 21(3)
- Publication Year :
- 2018
-
Abstract
- Novel insights into the pathophysiology of primary central nervous system lymphoma (PCNSL) have identified the B-cell receptor and Toll-like receptor pathway as well as immune evasion and suppressed tumor immune microenvironment as a key mechanism in the pathogenesis of PCNSL. Small molecules and novel agents targeting these aberrant pathways have been introduced into clinical trials targeting the recurrent or refractory PCNSL patient population. Agents like the Bruton tyrosine kinase (BTK) inhibitor ibrutinib or immunomodulatory drugs (IMiDs) like pomalidomide and lenalidomide have shown promising high response rates in the salvage setting. Here, we give an overview about the recent, exciting developments in PCNSL and summarize the results of clinical trials using novel agents in the recurrent and refractory salvage setting, which include immune checkpoint inhibitors, IMiDs, as well as BTK, phosphatidylinositol-3 kinase, and mammalian target of rapamycin inhibitors.
- Subjects :
- Cancer Research
Aminopyridines
Pathogenesis
Central Nervous System Neoplasms
chemistry.chemical_compound
Phosphatidylinositol 3-Kinases
0302 clinical medicine
Antineoplastic Agents, Immunological
Piperidines
hemic and lymphatic diseases
Agammaglobulinaemia Tyrosine Kinase
Lenalidomide
Phosphoinositide-3 Kinase Inhibitors
biology
Kinase
TOR Serine-Threonine Kinases
Toll-Like Receptors
Primary central nervous system lymphoma
Burkitt Lymphoma
Thalidomide
Oncology
030220 oncology & carcinogenesis
Ibrutinib
Lymphoma, Large B-Cell, Diffuse
Rituximab
medicine.drug
Morpholines
Lymphoma, T-Cell
03 medical and health sciences
Immune system
medicine
Bruton's tyrosine kinase
Humans
Immunologic Factors
Protein Kinase Inhibitors
Salvage Therapy
Invited Review
business.industry
Adenine
medicine.disease
Pomalidomide
Pyrimidines
chemistry
Cancer research
biology.protein
Pyrazoles
Tumor Escape
Neurology (clinical)
business
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 15235866
- Volume :
- 21
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Neuro-oncology
- Accession number :
- edsair.doi.dedup.....c36b7a25e5ae599b0603d8da42d08db7